Laboratory Corp. of America Holdings (NYSE:LH) has been downgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: September 17, 2016
Having a price of $138.05, Laboratory Corp. of America Holdings (NYSE:LH) traded 0.52% higher on the day. With the last stock price close up 5.97% from the 200-day average, compared to the S&P 500 Index which has decreased -0.01% over the same time period. The company has been tracking to a 50-day moving average of $138.33 and two hundred day average of $127.76. 802,175 shares of the stock traded, down from ann avg. volume of 822,431
Zacks Investment Research has downgraded Laboratory Corp. of America Holdings(NYSE:LH) to Hold in a report released 8/19/2016.
Previously on 8/16/2016, KeyBanc Capital Markets reported on Laboratory Corp. of America Holdings(NYSE:LH) upped the target price from $143.00 to $150.00 that suggested an upside of 0.08%.
See Graph Below:
Also covering Laboratory Corp. of America Holdings’s stock price target, a total of 17 brokers have reported on LH. The 12-month target is $140.94 with four analysts rating the company a strong buy, 10 analysts rating the company a buy, six analysts rating the stock a hold, 0 rating the company to underperform, and lastly 0 firms rating the stock as sell.
Laboratory Corp. of America Holdings has a P/E of 22 with a 52 week low of $97.79 and a 52 week high of $141.32. The company’s market cap is presently $0.0.
Brief Synopsis About Laboratory Corp. of America Holdings (NYSE:LH)
Laboratory Corporation of America Holdings is a healthcare diagnostics company. The Company, together with its subsidiaries, is engaged in providing clinical laboratory services and drug development support. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The Company’s LCD segment is an independent clinical laboratory business that consists of a network of approximately 40 primary laboratories and approximately 1, 700 patient service centers (PSCs) along with a network of branches and STAT laboratories, which offer a menu of routine and frequently ordered tests. LCD offers a menu of over 4, 700 tests, such as blood chemistry analyses, urinalyses, blood cell counts and thyroid tests. Its CDD segment offers drug development services, and provides a range of drug development solutions across the world, and primarily to companies in the pharmaceutical and biotechnology industries.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.